Remdesivir.

Q1 Pharmacology, Toxicology and Pharmaceutics Profiles of drug substances, excipients, and related methodology Pub Date : 2023-01-01 Epub Date: 2023-02-09 DOI:10.1016/bs.podrm.2022.11.003
Ahmed H Bakheit, Hany Darwish, Ibrahim A Darwish, Ahmed I Al-Ghusn
{"title":"Remdesivir.","authors":"Ahmed H Bakheit, Hany Darwish, Ibrahim A Darwish, Ahmed I Al-Ghusn","doi":"10.1016/bs.podrm.2022.11.003","DOIUrl":null,"url":null,"abstract":"<p><p>Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910426/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Profiles of drug substances, excipients, and related methodology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.podrm.2022.11.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
瑞德西韦
雷米地韦以 Veklury 品牌销售,是一种具有广泛活性的抗病毒药物。在 COVID-19 大流行期间,有多个国家批准使用 Remdesivir 治疗 COVID-19。Remdesivir 最初被设计用于治疗丙型肝炎,但后来对埃博拉病毒病和玛堡病毒感染进行了测试。雷米替韦是一种原药,旨在促进 GS-441524 单磷酸在细胞内的转运,并随后将其生物转化为 GS-441524 三磷酸,这是一种病毒 RNA 聚合酶的核糖核苷酸类似物抑制剂。本章旨在全面综述雷米替韦(GS-5734),包括其命名、理化性质、制备方法、鉴定程序、多种定性和定量分析技术、ADME 特征和药理作用。此外,本章还提供了多种色谱和光谱技术,用于在复方制剂中分离溴莫尼定和其他药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Profiles of drug substances, excipients, and related methodology
Profiles of drug substances, excipients, and related methodology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
13.10
自引率
0.00%
发文量
4
期刊最新文献
Avanafil: A comprehensive drug profile. Deferasirox: A comprehensive drug profile. Duvelisib: A comprehensive profile. Ponatinib: A comprehensive drug profile. Regorafenib: A comprehensive drug profile.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1